Results 111 to 120 of about 36,038 (221)
Family‐Wise Error Rate Control in Clinical Trials With Overlapping Populations
Statistics in Medicine, Volume 45, Issue 20-22, September 2026.ABSTRACT We consider clinical trials with multiple, overlapping patient populations that test multiple treatment policies specifically tailored to these populations. Such designs may lead to multiplicity issues, as false statements will affect several populations. For type I error control, often the family‐wise error rate (FWER) is controlled, which is
Remi Luschei, Werner Brannath
wiley +1 more source
Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials
IJTLD OpenBACKGROUND: In STAND and SimpliciTB, clinical trials for drug-susceptible TB, regimens containing pretomanid, pyrazinamide, and other agents (PaZX) had more hepatotoxicity than the standard-of-care regimen of isoniazid, rifampicin, pyrazinamide, and ...
J. Nedelman +9 more
doaj +1 more source
, 2016 We compare results of model simulation with data from [9] under Moxifloxacin treatment. Therapy starts 24 hours after infection and is continued every 12h.
Martin Witzenrath (167419) +7 more
core +1 more source
A Review on Green Synthetic Approaches in the Development of Quinoline Analogues
ChemistrySelect, Volume 11, Issue 33, 1 September 2026.This review highlights recent advances in environmentally friendly approaches, including metal‐free systems, solvent‐free approaches, microwave, and ultrasonic‐assisted techniques, organo‐ and biocatalysis, ionic liquids, nanoparticle catalysis, electrochemical, and photocatalytic strategies for the synthesis of quinoline scaffolds.
Demis Zelelew +3 more
wiley +1 more source
Activity of moxifloxacin against mycobacteria
, 1999 Moxifloxacin is an 8-methoxyquinolone compound with activity against a wide range of bacteria. We tested its activity in comparison with four other quinolones and isoniazid against clinical isolates of mycobacteria. It proved to be the most active of the
Gillespie, S. H., Billington, O.
core +1 more source
Topical Antibiotic Therapy in the Ocular Environment: The Benefits of Using Moxifloxacin Eyedrops
MicroorganismsMoxifloxacin is a fourth-generation fluoroquinolone antibiotic available for ophthalmic use. It inhibits two enzymes involved in bacterial DNA synthesis, covering Gram-positive and Gram-negative pathogens. This spectrum allows for the formulation of self-
Lorenzo Drago
doaj +1 more source
Clinical and Translational Science, Volume 19, Issue 9, September 2026.ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst +5 more
wiley +1 more source
, 2008 Mauro Campos, Mariana Ávila, Anelise Wallau, Cristina Muccioli, Ana Luisa Höfling-Lima, Rubens Belfort JrDepartment of Ophthalmology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo ...
Mariana Ávila +5 more
core
Veterinary Ophthalmology, Volume 29, Issue 5, September 2026.ABSTRACT Objective This study aimed to evaluate pre‐ and postoperative changes in the iridocorneal angle, ciliary cleft (CC), and ciliary muscle (CM) in canine eyes with intumescent cataracts using ultrasound biomicroscopy (UBM), with comparative reference to normal and non‐intumescent cataractous eyes.
Jiyi Hwang +7 more
wiley +1 more source
SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL ACTIVITIES OF BIOINORGANIC COMPLEXES OF MOXIFLOXACIN.
, 2019 Background: The growth of different organisms is controlled by drug-metal complexes which are injurious to humans. Moxifloxacin is one of the fourth generation fluoroquinolone antibiotics which inhibits DNA gyrase (a type II topoisomerase and ...
Fouzia Haider and Asia Naz. +1 more
core +1 more source